Logo image of ZYME

ZYMEWORKS INC (ZYME) Stock Fundamental Analysis

NASDAQ:ZYME - Nasdaq - US98985Y1082 - Common Stock - Currency: USD

14.24  -0.46 (-3.13%)

After market: 14.24 0 (0%)

Fundamental Rating

2

ZYME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of ZYME is average, but there are quite some concerns on its profitability. ZYME has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZYME had negative earnings in the past year.
In the past year ZYME has reported a negative cash flow from operations.
ZYME had negative earnings in 4 of the past 5 years.
ZYME had negative operating cash flow in 4 of the past 5 years.
ZYME Yearly Net Income VS EBIT VS OCF VS FCFZYME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

With a decent Return On Assets value of -23.33%, ZYME is doing good in the industry, outperforming 73.81% of the companies in the same industry.
The Return On Equity of ZYME (-30.97%) is better than 78.23% of its industry peers.
Industry RankSector Rank
ROA -23.33%
ROE -30.97%
ROIC N/A
ROA(3y)-18.57%
ROA(5y)-25.75%
ROE(3y)-28.45%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ZYME Yearly ROA, ROE, ROICZYME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 -40 -60 -80 -100

1.3 Margins

ZYME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYME Yearly Profit, Operating, Gross MarginsZYME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

ZYME does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZYME has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ZYME has been increased compared to 5 years ago.
Compared to 1 year ago, ZYME has a worse debt to assets ratio.
ZYME Yearly Shares OutstandingZYME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ZYME Yearly Total Debt VS Total AssetsZYME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

ZYME has an Altman-Z score of 2.71. This is not the best score and indicates that ZYME is in the grey zone with still only limited risk for bankruptcy at the moment.
ZYME has a better Altman-Z score (2.71) than 74.51% of its industry peers.
ZYME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ZYME has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACC10.71%
ZYME Yearly LT Debt VS Equity VS FCFZYME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

ZYME has a Current Ratio of 4.10. This indicates that ZYME is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.10, ZYME is in line with its industry, outperforming 46.90% of the companies in the same industry.
ZYME has a Quick Ratio of 4.10. This indicates that ZYME is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ZYME (4.10) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 4.1
ZYME Yearly Current Assets VS Current LiabilitesZYME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

ZYME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -141.03%.
The Revenue for ZYME has decreased by -86.53% in the past year. This is quite bad
The Revenue has been growing slightly by 7.48% on average over the past years.
EPS 1Y (TTM)-141.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.88%
Revenue 1Y (TTM)-86.53%
Revenue growth 3Y24.91%
Revenue growth 5Y7.48%
Sales Q2Q%-3.07%

3.2 Future

ZYME is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.05% yearly.
Based on estimates for the next years, ZYME will show a quite strong growth in Revenue. The Revenue will grow by 18.02% on average per year.
EPS Next Y14.96%
EPS Next 2Y-0.29%
EPS Next 3Y11.96%
EPS Next 5Y2.05%
Revenue Next Year14.37%
Revenue Next 2Y6.41%
Revenue Next 3Y31.33%
Revenue Next 5Y18.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZYME Yearly Revenue VS EstimatesZYME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
ZYME Yearly EPS VS EstimatesZYME Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZYME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZYME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYME Price Earnings VS Forward Price EarningsZYME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYME Per share dataZYME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.29%
EPS Next 3Y11.96%

More info and screens

0

5. Dividend

5.1 Amount

ZYME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYMEWORKS INC

NASDAQ:ZYME (2/4/2025, 8:17:49 PM)

After market: 14.24 0 (0%)

14.24

-0.46 (-3.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/amc
Earnings (Next)N/A N/A
Inst Owners96.62%
Inst Owner Change0.36%
Ins Owners0.02%
Ins Owner Change2.34%
Market Cap980.85M
Analysts84.29
Price Target20.85 (46.42%)
Short Float %6.84%
Short Ratio9.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.88%
Min EPS beat(2)3.34%
Max EPS beat(2)16.42%
EPS beat(4)3
Avg EPS beat(4)8.14%
Min EPS beat(4)-41.99%
Max EPS beat(4)54.79%
EPS beat(8)5
Avg EPS beat(8)2.12%
EPS beat(12)9
Avg EPS beat(12)9.64%
EPS beat(16)12
Avg EPS beat(16)9.58%
Revenue beat(2)1
Avg Revenue beat(2)-1.8%
Min Revenue beat(2)-6.1%
Max Revenue beat(2)2.5%
Revenue beat(4)2
Avg Revenue beat(4)-9.94%
Min Revenue beat(4)-43.59%
Max Revenue beat(4)7.41%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)6
Avg Revenue beat(12)6.55%
Revenue beat(16)7
Avg Revenue beat(16)-5.01%
PT rev (1m)0%
PT rev (3m)38.22%
EPS NQ rev (1m)19.79%
EPS NQ rev (3m)-80%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.2%
Revenue NQ rev (1m)4.1%
Revenue NQ rev (3m)9.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.77
P/FCF N/A
P/OCF N/A
P/B 2.67
P/tB 2.82
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0.9
BVpS5.33
TBVpS5.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.33%
ROE -30.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.57%
ROA(5y)-25.75%
ROE(3y)-28.45%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.98%
Cap/Sales 7.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 4.1
Altman-Z 2.71
F-Score3
WACC10.71%
ROIC/WACCN/A
Cap/Depr(3y)142.22%
Cap/Depr(5y)153.4%
Cap/Sales(3y)19.45%
Cap/Sales(5y)24.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-141.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.88%
EPS Next Y14.96%
EPS Next 2Y-0.29%
EPS Next 3Y11.96%
EPS Next 5Y2.05%
Revenue 1Y (TTM)-86.53%
Revenue growth 3Y24.91%
Revenue growth 5Y7.48%
Sales Q2Q%-3.07%
Revenue Next Year14.37%
Revenue Next 2Y6.41%
Revenue Next 3Y31.33%
Revenue Next 5Y18.02%
EBIT growth 1Y-159.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.19%
EBIT Next 3Y9.82%
EBIT Next 5YN/A
FCF growth 1Y76.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.68%
OCF growth 3YN/A
OCF growth 5YN/A